Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 11, 2021

Pneumagen starts trial of intranasal drug for respiratory tract infections

Neumifil demonstrated efficacy against Covid-19 in animal models by reducing clinical signs.

Pneumagen has commenced the Phase I clinical trial of its intranasal drug, Neumifil, in healthy subjects for viral respiratory tract infection (RTI) prophylaxis and treatment.

Generated using the company’s GlycoTarge technology, Neumifil is a new engineered multivalent carbohydrate-binding molecule (mCBM).

Designed as a self-administered nasal spray, the drug works by preventing the viruses from entering cells and migrating to the lungs.

Pneumagen is developing the therapy for various viral RTIs such as influenza and Covid-19.

The two-part, single-centre, double-blind, randomised, placebo-controlled trial will analyse the safety and tolerability of the universal drug in study subjects.

The safety and tolerability of single ascending intranasal doses of Neumifil will be analysed in Part A of the dose-escalating trial whereas Part B will investigate the safety and tolerability of the drug’s multiple ascending doses.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Pneumagen CEO Douglas Thomson said: “As an easy-to-use nasal spray that could be prescribed to those at risk of viral exacerbations, Neumifil has the potential to prevent more serious disease, hospitalisation and the need for critical care for patients.

“Neumifil is being developed as a safe, effective and convenient to self-administer option with the potential to transform the treatment of viral pandemics and infectious diseases.”

The company anticipates top-line data from the trial in the first half of next year.

Neumifil was found to be beneficial in the prevention, treatment and post-exposure prophylaxis of influenza and respiratory syncytial virus infection, without any toxicity reported in preclinical studies.

In animal models, the drug demonstrated efficacy against Covid-19 by substantially reducing clinical signs.

In April 2020, Pneumagen reported positive data from three in-vitro studies of Neumifil and other mCBMs to prevent Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU